Ipca Laboratories to sell Gujarat manufacturing unit for ₹22.15 crores

Ipca Laboratories Ltd. announced its Board of Directors approved the slump sale of its drug intermediates and active pharmaceutical ingredients manufacturing unit in Ankleshwar, Gujarat. The unit will be sold to M/s. Suleshvari Pharma Private Ltd. for ₹22.15 crores.

The transaction includes leasehold land, factory buildings, plant and machinery, employees, and business, and is subject to necessary approvals. The sale is expected to be completed by December 31, 2025, and aims to optimize manufacturing facilities, reduce smaller units, and lower overall administrative and operating costs.

The divested unit generated revenue of ₹50.24 crores (0.74% of total income) in the financial year ended March 31, 2025, with a written down value of ₹15.80 crores. M/s. Suleshvari Pharma Pvt. Ltd. is an independent entity, ensuring the transaction is not a related party deal. Ipca Laboratories stated this sale would not materially impact its business, financials, or shareholding pattern.